Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | YWHAZ | P63104 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10419819 | 1.00 | CA2 (0.35) | CA2CA1CA9MGAMGAA | |
| SCHEMBL7151445 | 1.00 | CA2 (0.35) | CA2CA1CA9MGAMGAA | |
| SCHEMBL28066823 | 1.00 | CA2 (0.35) | CA2CA1CA9MGAMGAA | |
| SCHEMBL27594926 | 0.94 | CA2 (0.36) | CA2CA1CA9MGAMGAA | |
| SCHEMBL9812954 | 0.94 | CA2 (0.36) | CA2CA1CA9MGAMGAA | |
| SCHEMBL16812682 | 0.85 | — | — | |
| SCHEMBL18026199 | 0.85 | CA2 (0.41) | CA2CA1CA9 | |
| SCHEMBL10482457 | 0.84 | CA2 (0.36) | CA2CA1CA9MGAMGAA | |
| SCHEMBL13985216 | 0.84 | CA2 (0.36) | CA2CA1CA9MGAMGAA | |
| SCHEMBL15892307 | 0.81 | CA2 (0.38) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110038952-A1 | GAMBOGIC ACID GLYCOSIDE DERIVATIVES AND ANALOGS, THEIR PREPARATION METHODS AND APPLICATIONS | XU LIFENG | 2011-02-17 | — | — | US | claimed |
| EP-2223929-A1 | GAMBOGIC GLYCOSIDE DERIVATIVES AND ANALOGS, THE PREPARATION AND THE APPLICATION THEREOF | Liaoning Lifeng Scientific&Technology Development Company Ltd. (CN) | 2010-09-01 | — | — | EP | claimed |
| EP-2675278-B1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | ALEXION PHARMA INTERNAT SÀRL (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | RIKEN (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | MTHFD2, ADH1B, DPYD | CA2 2795/4885CA1 2827/4885CA9 1203/4885 |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | MTHFD2, ADH1B, DPYD | CA2 2795/4885CA1 2827/4885CA9 1203/4885 |
| US-20110038952-A1 | GAMBOGIC ACID GLYCOSIDE DERIVATIVES AND ANALOGS, THEIR PREPARATION METHODS AND APPLICATIONS | PYGL, GYS2, G6PD | CA2 298/4885CA1 458/4885CA9 233/4885 |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | GBA1, UGCG, MAN2B1 | CA2 185/4885CA1 207/4885CA9 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.